Nirsevimab is a Monoclonal Antibody owned by AstraZeneca, and is involved in 7 clinical trials, of which 3 were completed, and 4 are ongoing.
Nirsevimab (MEDI-8897, SP-0232) is an RSV mAb. It acts by neutralizing the RSV-F protein. The antibody D25 binds to the RSV F protein prefusion complex. The cocrystal structure for one of these antibodies, D25, in complex with the F glycoprotein revealed D25 to lock F in its prefusion state by binding to a quaternary epitope at the trimer apex. They recognize a prefusion complex of the RSV-F protein. By targeting the RSV-F protein in the compact prefusion conformation, these antibodies could halt the critical unfolding of this protein into the conformation required for viral entry into cells.
The revenue for Nirsevimab is expected to reach a total of $17.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Nirsevimab NPV Report.
Nirsevimab (Beyfortus) is a human recombinant monoclonal antibody. It is formulated as a solution for the intramuscular route of administration. Beyfortus is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season.
Nirsevimab (MEDI-8897, SP-0232) is under development for the prevention of lower respiratory tract disease caused by respiratory syncytial virus infection in infants. It is administered intramuscularly as a solution. It is a D25 RSV-specific antibody and it is engineered with a triple-amino-acid (M252Y/S254T/T256E [YTE]) substitution within its Fc region. These antibodies are specific for the RSV-F protein. It is based on AIMSelect And AIMProve technology.
Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals and supplements. Sanofi‘s R&D efforts focus on advancing a combination drugs to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Asia-Pacific, Africa and the Middle East. Sanofi is headquartered in Paris, France.
The company reported revenues of (Euro) EUR39,175 million for the fiscal year ended December 2021 (FY2021), an increase of 4.8% over FY2020. In FY2021, the company’s operating margin was 20.7%, compared to an operating margin of 37.8% in FY2020. In FY2021, the company recorded a net margin of 15.9%, compared to a net margin of 32.9% in FY2020. The company reported revenues of EUR13,138 million for the third quarter ended September 2022, a decrease of 36.8% over the previous quarter.
Quick View – Nirsevimab
|Highest Development Stage|